 |
Welcome
TVM
Clinical Evidence
How to Buy / Clinical Training
US Reimbursement
Investor Relations
Contact Us
|
|
American Society of Anesthesiologists clinical paper alerts its members to the value of oesophageal Doppler monitoring (ODM) in surgery 25 April 2008 Deltex Medical Group plc ("Deltex Medical"), the UK's leading haemodynamic monitoring company, today notes the publication of a clinical review paper on oesophageal Doppler-guided fluid management during surgery in the monthly American Society of Anesthesiologists (ASA) communiqué to its members.
The authors also note that independent systematic reviews of the published data ("meta-analyses" and a US-government sponsored technology assessment) have confirmed the value of ODM in the surgical setting. Furthermore, the authors highlight that recent changes in reimbursement policy in the United States mean that doctors are able to charge for the use of ODM to guide fluid therapy during surgery or to assess haemodynamic status in ventilated patients in intensive care. The article was written by Professor Girish Joshi and Dr Ana Crawford both of the University of Texas Southwestern Medical Center, Dallas and can be accessed on-line at: www.asahq.org/Newsletters/2008/04-08/crawford04-08.html Deltex MedicalÕs Chief Executive, Andy Hill commented: "The American Society of Anesthesiologists is respected as the leading association of anaesthetists in the USA and one of its primary goals is to set practice standards in anaesthesia and pain management. "This paper brings the attention of the 42,000 practicing members of the ASA the key facts about the clinical value of ODM and alerts them to its new reimbursement status." For further information, please contact: Deltex Medical Group plc 01243 774 837 Gavin Anderson & Company 020 7554 1400 Charles Stanley Securities 020 7149 6000
Deltex Medical manufactures and markets the CardioQ™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body Š 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ™, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier. The CardioQ™ incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ™ provides clinicians with the ability to optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been proven to improve the speed and quality of patient recovery and reduce hospital stay. There are already around 1,500 CardioQ™s currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 90 clinical publications on the use of the CardioQ™ which have repeatedly:
The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ™ in a similar format and is used for taking snapshots or monitoring over short periods.
|